Overview of Tendinopathy, Peripheral Neuropathy, Aortic Aneurysm, and Hypoglycemia Caused by Fluoroquinolones

Author:

Balasubramanian Rajkapoor1ORCID,Maideen Naina Mohamed Pakkir2,Narayanaswamy Harikrishnan3

Affiliation:

1. Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Komarapalayam, Tamil Nadu, India

2. Pharmacy, Dubai Health Authority, Dubai, United Arab Emirates

3. Faculty of Pharmacy, Dr. M.G.R. Educational and Research Institute (Deemed to be University), A.C.S. Medical College and Hospital Campus, Velappanchavadi, Chennai, Tamil Nadu, India

Abstract

Abstract Background Fluoroquinolones (FQs) are widely used in the management of several bacterial infections including urinary tract infections (UTIs), upper respiratory tract infections (URTIs), lower respiratory tract infections (LRTIs), skin and soft tissue, gastrointestinal tract infections (GITIs), and many other infections. Objective This review article focuses on some serious side effects notified by United States Food and Drug Administration (US FDA) in different warning statements. Methods The literature was searched, in databases such as Medline/PubMed/PMC, Google Scholar, Science Direct, Ebsco, Scopus, Web of science, Embase, and reference lists to identify publications relevant to the serious side effects associated with the use of FQs. Results Several epidemiological studies and meta-analyses have documented the occurrence of serious side effects of FQs including tendinopathy, peripheral neuropathy, aortic aneurysm/dissection, hypoglycemia, QT prolongation, retinal detachment, and worsening of myasthenia gravis. Conclusion The clinicians should be aware of serious side effects of FQs. The US FDA and European Medicines Agency recommend against the use of FQs as first-line therapies to treat infections such as acute sinusitis, acute bronchitis, and uncomplicated UTIs, as the risks outweigh the benefits. The risk of incidence of serious side effects of FQs is higher among patients with advanced age, renal insufficiency, and certain concomitant medications. To avoid occurrence of any serious side effects of FQs, the clinicians should prefer non-FQ antibacterial drugs to manage uncomplicated UTIs, respiratory tract infections, and other infections for which alternatives available.

Publisher

Georg Thieme Verlag KG

Reference88 articles.

1. Fluoroquinolones: blessings or curses;P P Majalekar;Curr Drug Targets,2020

2. Recent updates of fluoroquinolones as antibacterial agents;H AA Ezelarab;Arch Pharm (Weinheim),2018

3. Mini review: is fluoroquinolone drug or poison?;F Z Mimouni;J Complexity in Health Sci,2019

4. Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules;J Fedorowicz;Monatsh Chem,2018

5. Fluoroquinolone antibiotics and adverse events;D Baggio;Aust Prescr,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3